Eli Lilly | LLY - Ebitda


Eli Lilly reported $10.29B in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
AbbVie USD 3.69B 1.68B Mar/2026
Abbott USD 2.43B 844M Mar/2026
ALKERMES USD 139.22M 58.96M Jun/2026
Amgen USD 3.86B 1.28B Mar/2026
AstraZeneca USD 5.16B 510M Jun/2026
Baxter International USD 309M 756M Mar/2026
Biogen USD 649.7M 76.5M Mar/2026
Bristol-Myers Squibb USD 4.24B 1.37B Mar/2026
Coherus Biosciences USD -43.33M 4.7M Sep/2025
Drreddys Laboratories INR 8.63B 12.96B Mar/2026
Eli Lilly USD 10.29B 1.86B Mar/2026
Gilead Sciences USD 3.51B 489M Mar/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
Glaxosmithkline GBP 2.77B 1.98B Mar/2026
J&J USD 8.27B 1.08B Mar/2026
Medtronic USD 2.81B 119M Mar/2026
Merck USD -1.54B 7.84B Mar/2026
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Novartis USD 6.48B 1.19B Jun/2026
Novartis USD 5.41B 431M Mar/2026
Novo Nordisk DKK 37.36B 2.64B Jun/2026
Perrigo USD 141.6M 1.34B Mar/2026
Pfizer USD 6.01B 18M Jun/2026
Phibro Animal Health USD 68.1M 6.2M Dec/2025
Prestige Brands USD 61.24M 23.31M Jun/2026
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Roche Holding CHF 13.43B 744M Jun/2026
Sanofi EUR 3.69B 375M Jun/2026
Sanofi EUR 2.72B 2.94B Mar/2026
United Therapeutics USD 355M 11.1M Jun/2026
Zoetis USD 939M 0 Mar/2026